MGF
Also known as: Mechano Growth Factor
A natural 'first responder' peptide that your muscles produce when they're damaged by exercise. It activates dormant muscle stem cells and kickstarts the repair process. Think of it as the signal that tells your body to start rebuilding after a workout. The problem is it only lasts 5-7 minutes in the body, making it extremely impractical — which is why the longer-lasting PEG-MGF version exists.
MGF (Mechano Growth Factor) is a splice variant of IGF-1 (Insulin-like Growth Factor-1) that is produced locally in muscle tissue in response to mechanical damage — in practical terms, after intense resistance training. It is sometimes called IGF-1Ec in humans and is one of the first signaling molecules released when a muscle fiber is damaged, making it a critical early step in the muscle repair cascade.
MGF's primary role is activating muscle satellite cells — dormant stem cells that sit between muscle fibers waiting for a damage signal. When MGF is released, these satellite cells "wake up," begin proliferating, and fuse with damaged muscle fibers to repair and enlarge them. This is a fundamentally different mechanism from IGF-1 LR3, which promotes overall growth and protein synthesis. MGF is specifically about initiating the repair response.
The major limitation of MGF is its extremely short half-life of just 5-7 minutes in the body. This makes practical dosing very difficult — the peptide is essentially cleared before it can reach distant tissues. For this reason, PEG-MGF (PEGylated Mechano Growth Factor) was developed, which extends the half-life to several hours through polyethylene glycol conjugation. Standard MGF is typically dosed at 200-400 mcg injected intramuscularly directly into the target muscle immediately post-workout, while PEG-MGF at 200-400 mcg can be injected subcutaneously and does not require site-specific injection.
Dosage
200-400 mcg intramuscular into target muscle post-workout
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Intramuscular injection (site-specific, post-workout)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Satellite Cell Activation
First responder in muscle repair — activates quiescent muscle stem cells.
Muscle Repair
Kickstarts the repair process in damaged muscle by activating dormant stem cells.
Mechanism of Action
Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents) that is produced locally in skeletal muscle in response to mechanical stress, stretch, or damage. Unlike the liver-derived systemic IGF-1Ea isoform, MGF is expressed transiently and locally at the site of muscle damage, making it the initial responder in the muscle repair cascade.
MGF's unique C-terminal E domain distinguishes it from other IGF-1 splice variants. This domain does not bind the IGF-1 receptor — instead, it has independent biological activity that activates quiescent satellite cells (muscle stem cells) residing between the sarcolemma and basal lamina of muscle fibers. MGF signaling drives these satellite cells from the G0 (quiescent) phase into the cell cycle, initiating proliferation. This proliferative burst expands the pool of myogenic precursor cells available for muscle repair.
The temporal sequence is critical to understanding MGF's role: mechanical damage triggers immediate MGF expression (peaking within hours), which activates and expands the satellite cell population. As MGF expression declines, the IGF-1Ea isoform takes over, driving the differentiation and fusion of activated satellite cells into existing myofibers for repair and hypertrophy. MGF essentially acts as the 'first responder' that determines how many satellite cells will be available for the subsequent repair process. Its extremely short half-life (5-7 minutes) is consistent with this role as a brief, localized signaling molecule rather than a sustained systemic factor. This rapid degradation is why the PEGylated version (PEG-MGF) was developed — to extend the biological window of satellite cell activation.
Regulatory Status
Not FDA approved. Research peptide. Academic interest for understanding muscle repair mechanisms.
Risks & Safety
Common
injection site pain, swelling, and tenderness.
Serious
no long-term data on effects of artificially activating muscle stem cells, very limited human research data.
Rare
scar tissue build-up, allergic reactions.
Compare MGF With
Research Papers
30Published: February 10, 2026
AI Summary
An African swine fever virus protein (MGF 505-3R) dampens immunity by tagging MyD88 for destruction and blocking interferon and NF-κB. A peptide from this protein reduced gut inflammation in mice, so it may be useful for inflammatory disease or as an antiviral target.
Published: November 10, 2025
AI Summary
Mangiferin slowed amyloid clumping of two peptides in a concentration-dependent way and reduced their toxicity to nerve cells. It may be a useful lead for drugs against Alzheimer's and related diseases.
Published: August 18, 2025
AI Summary
A coating of CAG peptides and polymer on a magnesium alloy stent slowed corrosion, improved blood compatibility, and favored endothelial over smooth muscle cell growth. The approach could improve biodegradable vascular stents.
Published: June 1, 2025
AI Summary
A coating of chondroitin sulfate and CAG peptides on a magnesium alloy improved corrosion resistance and blood compatibility while favoring endothelial cell growth. The strategy could support better biodegradable stents.
Published: May 11, 2025
AI Summary
A leaf extract of Gymnopodium floribundum showed anti-inflammatory effects in lab and animal tests, supporting its traditional use for inflammation and respiratory complaints in Mayan medicine.
Published: April 8, 2025
AI Summary
An African swine fever virus gene (MGF_360-4L) targets MDA5 for degradation via autophagy, blocking interferon signaling. Deleting this gene weakened the virus in pigs and could inform new vaccines.
Published: January 29, 2025
AI Summary
Insulin-producing cells from mouse gum fibroblasts were made and transplanted under the skin in capsules. The approach controlled blood sugar and improved survival in diabetic mice, supporting further work toward a diabetes cell therapy.
Published: March 8, 2025
AI Summary
Mangiferin protected the heart from ischemia-reperfusion injury in mice and cells by activating the GAS6/Axl pathway. It may be a useful cardioprotective agent.
Published: January 23, 2025
AI Summary
A coating of antimicrobial peptides on magnesium alloy slowed corrosion, reduced early bacterial growth, and promoted bone formation in rats. The design could improve orthopedic implants.
Published: December 4, 2024
AI Summary
Plasma proteomics was used to find biomarkers that may explain why hypertrophic cardiomyopathy affects patients so differently.
Published: October 29, 2024
AI Summary
Chickpea mutants tolerant to glyphosate were identified and had stronger antioxidant defenses. The work could support breeding herbicide-tolerant chickpea varieties.
Published: October 27, 2024
AI Summary
Shared genes and pathways link Alzheimer's with diabetes and obesity, including insulin signaling and energy metabolism. The analysis suggests new drug targets for Alzheimer's.
Published: September 30, 2024
AI Summary
Virus-like particles decorated with a sugar ligand and carrying a TLR7 agonist triggered dendritic cells to drive type 1 immunity and slow tumor growth in mice. The approach could advance cancer vaccines.
Published: November 11, 2024
AI Summary
Mechano-growth factor (MGF) was studied for its role in guiding periodontal ligament stem cell differentiation via Fyn-RhoA-YAP signaling.
Published: June 30, 2024
AI Summary
Two antibody-binding sites on an African swine fever virus protein (MGF_110-13L) were mapped. One site may be useful for diagnostic tests.
Published: June 28, 2024
AI Summary
Fucoidan and CAG peptides on a magnesium alloy improved corrosion resistance, blood compatibility, and endothelial cell growth while limiting smooth muscle cell growth. The approach could improve vascular stents.
Published: May 11, 2024
AI Summary
Lower bile acid levels were linked to heart problems in myeloma patients on carfilzomib. A metabolite-based risk score could help identify patients at higher risk before treatment.
Published: April 21, 2024
AI Summary
Transit-time flow measurement was analyzed in off-pump bypass patients to see how diabetes affects graft flow.
Published: January 17, 2024
AI Summary
Virus-like particles with a sugar ligand and TLR7 agonist drove dendritic cells to induce type 1 immunity and slow tumor growth in mice. The strategy could support new cancer vaccines.
Published: January 12, 2024
AI Summary
A single method was developed to detect multiple banned peptides in urine, including insulins, growth hormone releasers, IGFs, and mechano-growth factor, meeting anti-doping requirements.
Published: October 24, 2023
AI Summary
Children given SOBERANA vaccines had stronger antibody and T cell responses than those who had recovered from COVID-19, supporting vaccination in this age group.
Published: November 7, 2023
AI Summary
A new method was developed to align mass spectra of heavily modified peptides, which could help discover new modifications involved in disease.
Published: October 6, 2023
AI Summary
Machine learning was used to define inflammatory subgroups in schizophrenia and test whether they show different brain structure and cognition.
Published: May 11, 2023
AI Summary
Mechano-growth factor (MGF) affects chondrocyte behavior and cartilage repair and responds to mechanical load. The review summarizes its roles in joint health and disease.
Published: June 18, 2023
AI Summary
Removing the MGF-110-9L gene from African swine fever virus reduced TBK1 degradation and boosted interferon production, explaining why the deleted virus is weaker. The finding could inform vaccine design.
Published: May 4, 2023
AI Summary
Spinal cord injury was linked to new antibodies against spinal cord and neuronal targets, with local antibody production and complement activation. The work may inform autoimmune complications after injury.
Published: August 30, 2023
AI Summary
The FLOW trial was designed to test whether once-weekly semaglutide protects the kidneys in people with type 2 diabetes and chronic kidney disease.
Published: March 5, 2023
AI Summary
Cross-linked protein nanotubes improved delivery and absorption of mangiferin and were more effective than free drug in a diabetic mouse model.
Published: March 18, 2023
AI Summary
The study examined how total glucosides of white peony affect experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Published: June 23, 2023
AI Summary
IGF-1 and its splice form MGF support nerve repair under stress from low oxygen, inflammation, and oxidative damage. The review outlines their potential for treating nerve injury.
Frequently Asked Questions
What is MGF?
A natural 'first responder' peptide that your muscles produce when they're damaged by exercise. It activates dormant muscle stem cells and kickstarts the repair process. Think of it as the signal that tells your body to start rebuilding after a workout. The problem is it only lasts 5-7 minutes in the body, making it extremely impractical — which is why the longer-lasting PEG-MGF version exists.
What is MGF used for?
A natural 'first responder' peptide that your muscles produce when they're damaged by exercise. It activates dormant muscle stem cells and kickstarts the repair process. Think of it as the signal that tells your body to start rebuilding after a workout. The problem is it only lasts 5-7 minutes in the body, making it extremely impractical — which is why the longer-lasting PEG-MGF version exists.
What is the dosage for MGF?
Standard: 200-400 mcg intramuscular injected directly into target muscles immediately post-workout. Due to the extremely short half-life, PEG-MGF is often preferred for practical use.
What are the side effects of MGF?
Common: injection site pain, swelling, and tenderness. Serious: no long-term data on effects of artificially activating muscle stem cells, very limited human research data. Rare: scar tissue build-up, allergic reactions.
How does MGF work?
Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents) that is produced locally in skeletal muscle in response to mechanical stress, stretch, or damage. Unlike the liver-derived systemic IGF-1Ea isoform, MGF is expressed transiently and locally at the site of muscle damage, making it the initial responder in the muscle repair cascade. MGF's unique C-terminal E domain distinguishes it from other IGF-1 splice variants. This domain does not bind the IGF-1 receptor — instead, it has independent biological activity that activates quiescent satellite cells (muscle stem cells) residing between the sarcolemma and basal lamina of muscle fibers. MGF signaling drives these satellite cells from the G0 (quiescent) phase into the cell cycle, initiating proliferation. This proliferative burst expands the pool of myogenic precursor cells available for muscle repair. The temporal sequence is critical to understanding MGF's role: mechanical damage triggers immediate MGF expression (peaking within hours), which activates and expands the satellite cell population. As MGF expression declines, the IGF-1Ea isoform takes over, driving the differentiation and fusion of activated satellite cells into existing myofibers for repair and hypertrophy. MGF essentially acts as the 'first responder' that determines how many satellite cells will be available for the subsequent repair process. Its extremely short half-life (5-7 minutes) is consistent with this role as a brief, localized signaling molecule rather than a sustained systemic factor. This rapid degradation is why the PEGylated version (PEG-MGF) was developed — to extend the biological window of satellite cell activation.
How is MGF administered?
MGF is administered via intramuscular injection (site-specific, post-workout).
What is the half-life of MGF?
The half-life of MGF is 5-7 minutes.
Is MGF legal?
Not FDA approved. Research peptide. Academic interest for understanding muscle repair mechanisms.
Related Peptides
ACE-031
An experimental drug that acts as a 'decoy' to intercept myostatin and other muscle-limiting signals before they reach your muscles. It produced rapid muscle gains in clinical trials without any exercise. However, development was halted because it also accidentally blocked signals needed to maintain healthy blood vessels, causing nosebleeds and visible broken blood vessels. A powerful proof-of-concept that myostatin blocking works, but too dangerous in its current form.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
Ara-290
A peptide derived from EPO (the hormone that boosts red blood cells) but engineered to keep only the tissue-protective effects — it doesn't increase red blood cells at all. It activates the body's repair receptors to protect tissues and regenerate nerves. Particularly promising for nerve damage and tissue injury from poor blood flow. People use it for diabetic nerve damage and similar conditions.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.